Home > Neurology > EAN 2020 > Effects of galcanezumab on health-related quality of life

Effects of galcanezumab on health-related quality of life

Patients with treatment-resistant episodic or chronic migraine treated with the calcitonin gene-related peptide inhibitor galcanezumab reported better daily functioning and patient perception of health state, compared with placebo, as well as less disability. This was concluded from results of the CONQUER study [1].

Treatment resistance was defined as previous failure with 2 to 4 standard-of-care migraine preventive medication categories in the past 10 years due to inadequate efficacy and/or safety/tolerability issues. Participants were randomised to galcanezumab 120 mg/month (240 mg loading dose) or placebo for 3 months. Migraine Disability Assessment (MIDAS), European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L), and Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) scores were collected at baseline and month 3; MSQ as well at month 1 and 2.

In the intent-to treat (ITT)...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on